Eleonora Riva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eleonora Riva has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Erica Gentilin
Bioacoustics Research Laboratory, Department of Neurosciences, University of Padua, Padua, Italy
4 shared publications Simona Falletta
4 shared publicationsKatiuscia Benfini
3 shared publications- Maria Chiara Zatelli
Section of Endocrinology, Geriatrics and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
3 shared publications - Teresa Gagliano
Cancer Cell Signalling Lab, Department of Medicine, University of Udine, 33100 Udine, Italy
3 shared publications Uberti Ettore degli
3 shared publications
Latest Publications
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Magmas modulates chemoresistance in endocrine-related cancers
: Magmas, a gene encoding for the mitochondrial import inner membrane translocase subunit, Tim16, protects different cell lines from the antitumoral effects of several pro-apoptotic stimuli (i.e. chemicals and chemotherapeutic agents). The synthetic Compound 5 is capable of sensitizing chemoresistant tumor cells overexpressing Magmas to proapoptotic stimuli, indicating that this molecule may be useful to overcome tumor chemoresistance. The aim of our study was to evaluate whether Compound 5 targets Tim16 and is cytotoxic in vivo. We found that Compound 5 enhances the antiproliferative effects of doxorubicin in MCF7 cells, while it fails to do so in two independent MCF7 cell clones where Magmas was silenced by specific shRNA. Then, the normal breast MCF12 cells were transfected with two differently tagged vectors, tim16-ddktag encoding for Tim16 and tim14-hatag, encoding for its partner Tim14. We found that Tim16 co-immunoprecipitates with Tim14 and that their interaction is reduced in the presence of Compound 5. However, Tim16 levels appear to be reduced in cells treated with Compound 5. The toxicity of this molecule was then tested in vivo by the Fish Embryo toxicity assay, employing Zebrafish eggs: Compound 5 is not toxic in vivo at the concentrations employed in vitro (5 and 10 μM), while its toxicity increases dose-dependently at higher concentrations. These data support the hypothesis that Compound 5 targets Tim16 and that Tim16 levels modulate the chemosensitizing effects of Compound 5, that need to be confirmed by in vivo studies.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Magmas modulates chemoresistance in endocrine-related cancers
: Magmas, a gene encoding for the mitochondrial import inner membrane translocase subunit, Tim16, protects different cell lines from the antitumoral effects of several pro-apoptotic stimuli (i.e. chemicals and chemotherapeutic agents). The synthetic Compound 5 is capable of sensitizing chemoresistant tumor cells overexpressing Magmas to proapoptotic stimuli, indicating that this molecule may be useful to overcome tumor chemoresistance. The aim of our study was to evaluate whether Compound 5 targets Tim16 and is cytotoxic in vivo. We found that Compound 5 enhances the antiproliferative effects of doxorubicin in MCF7 cells, while it fails to do so in two independent MCF7 cell clones where Magmas was silenced by specific shRNA. Then, the normal breast MCF12 cells were transfected with two differently tagged vectors, tim16-ddktag encoding for Tim16 and tim14-hatag, encoding for its partner Tim14. We found that Tim16 co-immunoprecipitates with Tim14 and that their interaction is reduced in the presence of Compound 5. However, Tim16 levels appear to be reduced in cells treated with Compound 5. The toxicity of this molecule was then tested in vivo by the Fish Embryo toxicity assay, employing Zebrafish eggs: Compound 5 is not toxic in vivo at the concentrations employed in vitro (5 and 10 μM), while its toxicity increases dose-dependently at higher concentrations. These data support the hypothesis that Compound 5 targets Tim16 and that Tim16 levels modulate the chemosensitizing effects of Compound 5, that need to be confirmed by in vivo studies.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Study of different in vitro systems for the evalutation of Sunitinib effects in pancreatic neuroendocrine tumour cells
Finding new preclinical models to study the effects of anticancer drugs is one of the aims of biomedical research. Indeed, testing different in vitro systems can lead to a better understanding of the molecular pathways regulating tumor development and growth, and help to find new therapeutic approaches. This is crucial especially in the settings of pancreatic neuroendocrine tumours (pNET), where one of the main drugs approved for medical treatment is Sunitinib, a multi-targeted receptor kinase inhibitor. Clarifying the effects of this drug may be important to develop more effective medical treatment, therefore we tested Sunitinib on the human pNET cell line, BON1, grown in two different in vitro systems, monolayer and spheroid, in order to understand the different effects of the drug in 2D and 3D settings. BON1 cells were grown in monolayer and treated with Sunitinib at increasing concentrations (0.25–5 μM). Cell Proliferation Assay and Luminescent Cell Viability Assay were employed to test Sunitinib antiproliferative effects. We found that Sunitinib 5 μM significantly reduced BON1 cell viability by 30% (PPP<0.05 vs control) after 7 days. Then, BON1 cells were grown in spheroids with Sunitinib at increasing concentrations (0.25–5 μM). Spheroids size was analyzed with ImageJ software after 3 and 7 days. We found that Sunitinib does not affect spheroid size, but induces spheroid disgregation after 7 days of treatment at 5 μM. These results indicate that measuring spheroid diameter in a 3D system is not the optimal system to assess the antiproliferative effects of Sunitinib on BON1 cells. On the other hand, the differences observed between the employed models could reflect the variations in drug response depending on cell aggregation state.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Study of different in vitro systems for the evalutation of Sunitinib effects in pancreatic neuroendocrine tumour cells
Finding new preclinical models to study the effects of anticancer drugs is one of the aims of biomedical research. Indeed, testing different in vitro systems can lead to a better understanding of the molecular pathways regulating tumor development and growth, and help to find new therapeutic approaches. This is crucial especially in the settings of pancreatic neuroendocrine tumours (pNET), where one of the main drugs approved for medical treatment is Sunitinib, a multi-targeted receptor kinase inhibitor. Clarifying the effects of this drug may be important to develop more effective medical treatment, therefore we tested Sunitinib on the human pNET cell line, BON1, grown in two different in vitro systems, monolayer and spheroid, in order to understand the different effects of the drug in 2D and 3D settings. BON1 cells were grown in monolayer and treated with Sunitinib at increasing concentrations (0.25–5 μM). Cell Proliferation Assay and Luminescent Cell Viability Assay were employed to test Sunitinib antiproliferative effects. We found that Sunitinib 5 μM significantly reduced BON1 cell viability by 30% (PPP<0.05 vs control) after 7 days. Then, BON1 cells were grown in spheroids with Sunitinib at increasing concentrations (0.25–5 μM). Spheroids size was analyzed with ImageJ software after 3 and 7 days. We found that Sunitinib does not affect spheroid size, but induces spheroid disgregation after 7 days of treatment at 5 μM. These results indicate that measuring spheroid diameter in a 3D system is not the optimal system to assess the antiproliferative effects of Sunitinib on BON1 cells. On the other hand, the differences observed between the employed models could reflect the variations in drug response depending on cell aggregation state.
- Open Access
- 28 March 2017
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 6
Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression
Thyroid cancer is common, yet the sequence of alterations that promote tumor formation are incompletely understood. Here, we describe a novel model of thyroid carcinoma in zebrafish that reveals temporal changes due to BRAFV600E. Through the use of real-time in vivo imaging, we observe disruption in thyroid follicle structure that occurs early in thyroid development. Combinatorial treatment using BRAF and MEK inhibitors reversed the developmental effects induced by BRAFV600E. Adult zebrafish expressing BRAFV600E in thyrocytes developed invasive carcinoma. We identified a gene expression signature from zebrafish thyroid cancer that is predictive of disease-free survival in patients with papillary thyroid cancer. Gene expression studies nominated TWIST2 as a key effector downstream of BRAF. Using CRISPR/Cas9 to genetically inactivate a TWIST2 orthologue, we suppressed the effects of BRAFV600E and restored thyroid morphology and hormone synthesis. These data suggest that expression of TWIST2 plays a role in an early step of BRAFV600E-mediated transformation.
- 28 March 2017
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 6
Open AccessOncogenic BRAF disrupts thyroid morphogenesis and function via twist expression
Thyroid cancer is common, yet the sequence of alterations that promote tumor formation are incompletely understood. Here, we describe a novel model of thyroid carcinoma in zebrafish that reveals temporal changes due to BRAFV600E. Through the use of real-time in vivo imaging, we observe disruption in thyroid follicle structure that occurs early in thyroid development. Combinatorial treatment using BRAF and MEK inhibitors reversed the developmental effects induced by BRAFV600E. Adult zebrafish expressing BRAFV600E in thyrocytes developed invasive carcinoma. We identified a gene expression signature from zebrafish thyroid cancer that is predictive of disease-free survival in patients with papillary thyroid cancer. Gene expression studies nominated TWIST2 as a key effector downstream of BRAF. Using CRISPR/Cas9 to genetically inactivate a TWIST2 orthologue, we suppressed the effects of BRAFV600E and restored thyroid morphology and hormone synthesis. These data suggest that expression of TWIST2 plays a role in an early step of BRAFV600E-mediated transformation.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
mTOR pathway: its role in regulating GH secretion in a rat pituitary adenoma cell line
Acromegaly results from excess growth hormone (GH) secretion, due to a pituitary adenoma. Surgery is the first option recommended for treatment of GH secreting pituitary adenomas; medical therapy, mostly represented by somatostatin analogues (SSA), is most often used if surgery is not successful. Insulin-like Growth Factor-1 (IGF-1) physiologically reduces GH levels through an endocrine negative feedback loop. IGF-1 exerts its effects also through PI3K/Akt/mTOR pathway activation and regulates different cellular processes. The aim of this study is to understand whether PI3K/Akt/mTOR pathway can influence IGF-1 feed-back in a rat pituitary adenoma cell line (GH3 cells). We used three inhibitors: Everolimus (mTOR inhibitor), NVP-BEZ235 (mTOR and PI3K inhibitor) and LY294002 (PI3K inhibitor) in the presence or in the absence of IGF-1. We evaluated cell viability by ATPlite Assay, GH secretion by ELISA and Akt phosphorylation by Western blot. We found that cell viability was induced by IGF-1 (+30%) and reduced by Everolimus up to 30%; this effect was not counteracted by IGF-1. NVP-BEZ235 reduced cell viability and IGF-1 counteracted this effect. GH secretion was reduced by IGF-1 (40%); this effect was not affected by Everolimus, but was blocked by NVP-BEZ235. Moreover, IGF-1 induced Akt phosphorylation, that was enhanced by Everolimus and completely abolished by NVP-BEZ235. To validate these results, we assessed LY294002 alone and with IGF-1, confirming that IGF1 increases Akt phosphorylation while LY294002 arrest this effect. These results show that IGF-1 is an important regulator of cell proliferation and GH secretion in pituitary cells and that PI3K/Akt/mTOR inhibitors may modulate IGF-1 signaling. This pathway has a role in IGF-1 negative feedback on GH secretion, through Akt inhibition. Therefore, mTOR pathway may represent a possible target for treatment of GH-secreting pituitary adenomas.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
mTOR pathway: its role in regulating GH secretion in a rat pituitary adenoma cell line
Acromegaly results from excess growth hormone (GH) secretion, due to a pituitary adenoma. Surgery is the first option recommended for treatment of GH secreting pituitary adenomas; medical therapy, mostly represented by somatostatin analogues (SSA), is most often used if surgery is not successful. Insulin-like Growth Factor-1 (IGF-1) physiologically reduces GH levels through an endocrine negative feedback loop. IGF-1 exerts its effects also through PI3K/Akt/mTOR pathway activation and regulates different cellular processes. The aim of this study is to understand whether PI3K/Akt/mTOR pathway can influence IGF-1 feed-back in a rat pituitary adenoma cell line (GH3 cells). We used three inhibitors: Everolimus (mTOR inhibitor), NVP-BEZ235 (mTOR and PI3K inhibitor) and LY294002 (PI3K inhibitor) in the presence or in the absence of IGF-1. We evaluated cell viability by ATPlite Assay, GH secretion by ELISA and Akt phosphorylation by Western blot. We found that cell viability was induced by IGF-1 (+30%) and reduced by Everolimus up to 30%; this effect was not counteracted by IGF-1. NVP-BEZ235 reduced cell viability and IGF-1 counteracted this effect. GH secretion was reduced by IGF-1 (40%); this effect was not affected by Everolimus, but was blocked by NVP-BEZ235. Moreover, IGF-1 induced Akt phosphorylation, that was enhanced by Everolimus and completely abolished by NVP-BEZ235. To validate these results, we assessed LY294002 alone and with IGF-1, confirming that IGF1 increases Akt phosphorylation while LY294002 arrest this effect. These results show that IGF-1 is an important regulator of cell proliferation and GH secretion in pituitary cells and that PI3K/Akt/mTOR inhibitors may modulate IGF-1 signaling. This pathway has a role in IGF-1 negative feedback on GH secretion, through Akt inhibition. Therefore, mTOR pathway may represent a possible target for treatment of GH-secreting pituitary adenomas.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Human endometrial adenocarcinoma: growth hormone involvement in cancer chemoresistance
Introduction: It is known that growth hormone (GH) may influence neoplastic development of endometrial epithelium. GH is produced by normal and neoplastic endometrial cells and elevated levels have been observed in endometrial epithelium of patients with endometriosis and endometrial adenocarcinoma (EA). Moreover, endometrium cancer is one of the most occurring tumors in acromegalic patients. Furthermore, autocrine GH increases the oncogenicity of EA cells and is considered fundamental in neoplastic progression. Since chemoresistance often develops in advanced EA, we aimed at investigating whether GH might influence the development of chemoresistance to drugs routinely employed in EA treatment. Description of methods: To this aim we employed two EA cell lines: HEC-1-A and AN3 CA cells. Cell viability and caspase activation were assessed by CellTiter-Glo Luminescent Cell Viability Assay (Promega) and Caspase-Glo 3/7 Assay (Promega), respectively. The expression of protein chinase C delta (PRKCD) was investigated by Western-blotting. Results: We demonstrated that GH increases the viability of EA cell lines, while doxorubicin, cisplatin and paclitaxel significantly reduce this parameter. GH was capable to blunt the effects of doxorubicin and cisplatin, but did not influence paclitaxel effects on cell viability. GH also protects EA cells from caspase activation induced by doxorubicin and cisplatin. In addition, doxorubicin and cisplatin induce PRKCD expression, an effect counteracted by GH. Conclusion: All together our results suggest that GH may contribute to EA chemoresistance by interfering with apoptotic mechanisms. This may provide new insights on novel therapies against EA chemoresistant aggressive tumors.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Human endometrial adenocarcinoma: growth hormone involvement in cancer chemoresistance
Introduction: It is known that growth hormone (GH) may influence neoplastic development of endometrial epithelium. GH is produced by normal and neoplastic endometrial cells and elevated levels have been observed in endometrial epithelium of patients with endometriosis and endometrial adenocarcinoma (EA). Moreover, endometrium cancer is one of the most occurring tumors in acromegalic patients. Furthermore, autocrine GH increases the oncogenicity of EA cells and is considered fundamental in neoplastic progression. Since chemoresistance often develops in advanced EA, we aimed at investigating whether GH might influence the development of chemoresistance to drugs routinely employed in EA treatment. Description of methods: To this aim we employed two EA cell lines: HEC-1-A and AN3 CA cells. Cell viability and caspase activation were assessed by CellTiter-Glo Luminescent Cell Viability Assay (Promega) and Caspase-Glo 3/7 Assay (Promega), respectively. The expression of protein chinase C delta (PRKCD) was investigated by Western-blotting. Results: We demonstrated that GH increases the viability of EA cell lines, while doxorubicin, cisplatin and paclitaxel significantly reduce this parameter. GH was capable to blunt the effects of doxorubicin and cisplatin, but did not influence paclitaxel effects on cell viability. GH also protects EA cells from caspase activation induced by doxorubicin and cisplatin. In addition, doxorubicin and cisplatin induce PRKCD expression, an effect counteracted by GH. Conclusion: All together our results suggest that GH may contribute to EA chemoresistance by interfering with apoptotic mechanisms. This may provide new insights on novel therapies against EA chemoresistant aggressive tumors.
- 1 December 2015
- Published by Elsevier in Biochemical Pharmacology
- Vol. 98 (4) , 639-648
Inhibition of epithelial growth factor receptor can play an important role in reducing cell growth and survival in adrenocortical tumors
- 1 December 2015
- Published by Elsevier in Biochemical Pharmacology
- Vol. 98 (4) , 639-648
Inhibition of epithelial growth factor receptor can play an important role in reducing cell growth and survival in adrenocortical tumors
- Open Access
- 1 June 1997
- Published by Elsevier in Annals of Oncology
- Vol. 8 (6) , 561-567
Delayed emesis induced by moderately emetogenic chemotherapy: Do we need to treat all patients?
- 1 June 1997
- Published by Elsevier in Annals of Oncology
- Vol. 8 (6) , 561-567
Open AccessDelayed emesis induced by moderately emetogenic chemotherapy: Do we need to treat all patients?